FDA & EC Biosimilar Approvals Boost PJIA Drug Growth The Polyarticular Juvenile Idiopathic Arthritis (PJIA) Drugs Market size was valued at USD 1,588.40 million in 2021 and is estimated to reach at a CAGR of 6.60% over the forecast period 2024–2031. This steady growth is being fueled by the expanding availability of next-generation biologics, increasing regulatory approvals in the US and Japan, and a rising incidence of pediatric arthritis...
0 Compartilhamentos
9 Visualizações
0 Anterior